MFDS
- Status: likely_approved
🇰🇷 Kyprolis in South Korea
Kyprolis (carfilzomib) regulatory status in South Korea.
Marketing authorisation
Kyprolis in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in South Korea
Frequently asked questions
Is Kyprolis approved in South Korea?
Yes. MFDS has authorised it.
Who is the marketing authorisation holder for Kyprolis in South Korea?
Amgen is the originator. The local marketing authorisation holder may differ — check the official source linked above.